Metformin with temozolomide for newly diagnosed glioblastoma: results of phase i study and a brief review of relevant studies

HIGHLIGHTS

• who: Makoto Ohno and collaborators from the Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan Department of Molecular Cancer Science, Faculty of Medicine, Yamagata University have published the paper: Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies, in the Journal: Cancers 2022, 4222 of /2022/
• what: The authors design a phase I/II study to examine the clinical effect of MF. The authors aim to determine a recommended phase II MF dose with maintenance temozolomide (TMZ) in patients with GBM . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.